[go: up one dir, main page]

ECSP003792A - CRYSTAL OF 4-CARBOXAMINO-1,2,3,4-TETRAHYDROQUINOLINE 2-REPLACED - Google Patents

CRYSTAL OF 4-CARBOXAMINO-1,2,3,4-TETRAHYDROQUINOLINE 2-REPLACED

Info

Publication number
ECSP003792A
ECSP003792A EC2000003792A ECSP003792A ECSP003792A EC SP003792 A ECSP003792 A EC SP003792A EC 2000003792 A EC2000003792 A EC 2000003792A EC SP003792 A ECSP003792 A EC SP003792A EC SP003792 A ECSP003792 A EC SP003792A
Authority
EC
Ecuador
Prior art keywords
carboxamino
tetrahydroquinoline
crystal
replaced
crystals
Prior art date
Application number
EC2000003792A
Other languages
Spanish (es)
Inventor
Derek Lawrence Tickner
Lyle R Brostrom
Troy Anthony Appleton
Allen Douglas John Meldrum
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ECSP003792A publication Critical patent/ECSP003792A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

Se describen formas crsitalinas de un inhibidor de CETP, procedimientos para preparar los crsitales, procedimientos de uso de los cristales y composiciones farmacéuticas que contienen los cristales.Crsitaline forms of a CETP inhibitor, methods for preparing the crsitals, methods of using the crystals and pharmaceutical compositions containing the crystals are described.

EC2000003792A 1999-11-30 2000-11-29 CRYSTAL OF 4-CARBOXAMINO-1,2,3,4-TETRAHYDROQUINOLINE 2-REPLACED ECSP003792A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16805199P 1999-11-30 1999-11-30

Publications (1)

Publication Number Publication Date
ECSP003792A true ECSP003792A (en) 2002-04-23

Family

ID=22609901

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2000003792A ECSP003792A (en) 1999-11-30 2000-11-29 CRYSTAL OF 4-CARBOXAMINO-1,2,3,4-TETRAHYDROQUINOLINE 2-REPLACED

Country Status (28)

Country Link
EP (1) EP1246804A1 (en)
JP (1) JP2003515592A (en)
KR (1) KR20020058057A (en)
CN (1) CN1402711A (en)
AP (1) AP2002002531A0 (en)
AU (1) AU1048801A (en)
BG (1) BG106854A (en)
BR (1) BR0015836A (en)
CA (1) CA2392979A1 (en)
CO (1) CO5271716A1 (en)
EA (1) EA200200510A1 (en)
EC (1) ECSP003792A (en)
EE (1) EE200200277A (en)
GT (1) GT200000199A (en)
HU (1) HUP0203521A2 (en)
IL (1) IL149097A0 (en)
IS (1) IS6338A (en)
MA (1) MA26845A1 (en)
MX (1) MXPA02005354A (en)
NO (1) NO20022558D0 (en)
OA (1) OA12099A (en)
PA (1) PA8506301A1 (en)
PE (1) PE20010904A1 (en)
PL (1) PL355892A1 (en)
TN (1) TNSN00231A1 (en)
TR (1) TR200201446T2 (en)
UY (1) UY26454A1 (en)
WO (1) WO2001040190A1 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115279B2 (en) 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
PL368850A1 (en) 2001-06-21 2005-04-04 Pfizer Products Inc. Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors
GT200200170A (en) 2001-09-28 2003-05-23 PREPARATION OF INHIBITOR OF CETP ANHIDRO
EP1920766B1 (en) * 2002-02-01 2017-08-23 Bend Research, Inc Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
WO2003063822A2 (en) * 2002-02-01 2003-08-07 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
WO2003063833A1 (en) 2002-02-01 2003-08-07 Pfizer Products Inc. Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
US7332514B2 (en) 2002-08-30 2008-02-19 Japan Tobacco Inc. Dibenzylamine compound and medicinal use thereof
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
KR20050055747A (en) 2002-10-04 2005-06-13 밀레니엄 파머슈티컬스 인코퍼레이티드 Pgd2 receptor antagonists for the treatment of inflammatory diseases
CA2508840A1 (en) 2002-12-20 2004-07-08 Pfizer Products Inc. Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
KR20050110017A (en) 2003-03-17 2005-11-22 니뽄 다바코 산교 가부시키가이샤 Method for increasing the oral bioavailability of s-'2-(''1-(2-ethylbutyl)cyclohexyl!carbonyl!amino)phenyl!-2-methylpropanethioate
OA13153A (en) * 2003-03-28 2006-12-13 Pfizer Prod Inc 1,2,4-substituted 1,2,3,4-tetrahydro-and 1,2 dihydro-quinoline and 1,2,3,4-tetrahydroquinoxaline derivatives as CETP inhibitors for the treatment of atherosclerosis and obesity.
CA2532931A1 (en) 2003-08-04 2005-02-10 Pfizer Products Inc. Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials
AU2004282101A1 (en) 2003-10-08 2005-04-28 Eli Lilly And Company Compounds and methods for treating dyslipidemia
CN1942428A (en) * 2004-04-13 2007-04-04 默克公司 CETP inhibitors
BRPI0512523A (en) * 2004-06-24 2008-03-11 Lilly Co Eli compound or a pharmaceutically acceptable salt, enantiomer, racemate, diastereomer or mixture of diastereomers thereof, pharmaceutical composition, and use of a compound
WO2006033001A1 (en) * 2004-09-23 2006-03-30 Pfizer Products Inc. Quinoline compounds
US20070149567A1 (en) * 2004-09-23 2007-06-28 Pfizer Inc Quinoline compounds
JP2008543726A (en) 2005-02-24 2008-12-04 ミレニアム・ファーマシューティカルズ・インコーポレイテッド PGD2 receptor antagonist for the treatment of inflammatory diseases
WO2006098394A1 (en) * 2005-03-14 2006-09-21 Japan Tobacco Inc. Method for inhibiting lipid absorption and lipid absorption inhibitor
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
AR065670A1 (en) 2007-03-09 2009-06-24 Indigene Pharmaceuticals Inc COMBINATION OF METFORMIN R - (+) LIPOATE AND ANTIHIPERLIPIDEMIC AGENTS FOR THE TREATMENT OF DIABETIC HYPERGLUCEMIA AND DIABETIC COMPLICATIONS
US20110245209A1 (en) 2008-12-16 2011-10-06 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
WO2010075069A1 (en) 2008-12-16 2010-07-01 Schering Corporation Bicyclic pyranone derivatives as nicotinic acid receptor agonists
TWI450896B (en) 2009-06-30 2014-09-01 Lilly Co Eli Trans-4-[[(5s)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl](2-methyl-2h-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1h-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid
ES2825675T3 (en) 2014-07-30 2021-05-17 Hoffmann La Roche Genetic markers to predict reactivity to treatment with an agent that increases HDL or that mimics HDL

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231102A (en) * 1989-03-08 1993-07-27 Merck Sharp & Dohme, Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
AU5731098A (en) * 1997-02-03 1998-08-25 American Home Products Corporation 2-substituted-1-acyl-1,2-dihydroquinoline derivatives to increase hdl-cholesterol level
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines

Also Published As

Publication number Publication date
TNSN00231A1 (en) 2002-05-30
OA12099A (en) 2006-05-04
MA26845A1 (en) 2004-12-20
GT200000199A (en) 2002-05-23
UY26454A1 (en) 2001-07-31
BG106854A (en) 2002-12-29
EA200200510A1 (en) 2002-10-31
EP1246804A1 (en) 2002-10-09
EE200200277A (en) 2003-10-15
CO5271716A1 (en) 2003-04-30
PA8506301A1 (en) 2002-08-26
PL355892A1 (en) 2004-05-31
IS6338A (en) 2002-04-12
JP2003515592A (en) 2003-05-07
NO20022558L (en) 2002-05-29
NO20022558D0 (en) 2002-05-29
AU1048801A (en) 2001-06-12
CA2392979A1 (en) 2001-06-07
WO2001040190A1 (en) 2001-06-07
IL149097A0 (en) 2002-11-10
TR200201446T2 (en) 2002-11-21
KR20020058057A (en) 2002-07-12
HUP0203521A2 (en) 2003-02-28
AP2002002531A0 (en) 2002-06-30
BR0015836A (en) 2002-08-06
MXPA02005354A (en) 2002-12-11
CN1402711A (en) 2003-03-12
PE20010904A1 (en) 2001-09-10

Similar Documents

Publication Publication Date Title
ECSP003792A (en) CRYSTAL OF 4-CARBOXAMINO-1,2,3,4-TETRAHYDROQUINOLINE 2-REPLACED
UY24555A1 (en) NEW COMPOUNDS
ES2144192T3 (en) NEW DERIVATIVES OF 1-PHENYL-2-DIMETHYL-AMINO-METHYL-CICLOHEXAN-1-OL, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
GT199900102A (en) PHENOXIPROPANOLAMINES, PROCEDURE FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
MX9102501A (en) METHANE SULFONAMIDE DERIVATIVES, FARDERIVED COMPOSITIONS OF METHANOSULFONAMIDE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCEDURE FOR SMACEUTICS THAT CONTAIN THEM AND PROCEDURE FOR U PREPARATION. ITS PREPARATION.
BR0111667A (en) New compounds
DK1007520T3 (en) 2-aminopyridines containing linked ring substituents as NOS inhibitors
AR021355A1 (en) DERIVATIVES OF QUINOLINA. PROCEDURE FOR THE PREPARATION, PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM, AND THE USE OF THEM FOR THE MANUFACTURE OF A MEDICINE
ES2133543T3 (en) PIRROLIDINE AND OXAZOLIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF THE THROMBOCYTE AGGREGATION.
ES2178055T3 (en) SUBSTITUTED AMINIC DERIVATIVES, THEIR PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
NO934628L (en) Retroviral protease inhibitors
FI934298A0 (en) CRYSTAL TIAGABINE HYDROCHLORIDE MONOHYDRATE, DESS FRAMSTAELLNING OCH DESS ANVAENDNING
ECSP034531A (en) SUBSTITUTED DERIVATIVES OF C-CICLOHEXILMETILAMINA
AR028443A1 (en) NEW COMPOUNDS DERIVED FROM PIPERAZINE AND PIPERIDINE, METHOD FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND PREPARATION OF THE SAME AND USE OF SUCH COMPOUNDS
HN2001000235A (en) DERIVATIVES BRIDGES OF PIPERAZINA
DK1051177T3 (en) Steroidal 3-O-Sulfamate derivatives as inhibitors of oestrone sulfatase
IS4367A (en) CCK or gastrin attenuating 5-heterocyclic-1,5-benzodiazepines
MX9603092A (en) NEW COMPOUNDS WITH ANALGESIC EFFECT AND LOCAL ANESTHETIC.
MX9303572A (en) PROTEASE INHIBITORS OF THE HUMAN IMMUNODEFICIENCY SYNDROME, PROCEDURE FOR THEIR PREPARATION AND PHARMACEUTICAL FORMULATION CONTAINING THEM.
MX9704034A (en) DERIVATIVES AND COMPOSITIONS OF SUBSTITUTED 2-ARYLCARBONYLOXYMETHYL-1,2,5-TIADIAZOLIDIN-3-ONA 1,1-DIOXIDE AND METHOD OF USE.
ES2186989T3 (en) MALTITOL CRYSTALS OF SPECIFIC FORMS, CRYSTAL COMPOUNDS THAT CONTAIN THEM AND PROCEDURES FOR THEIR PREPARATION.
MX9601635A (en) Anthracycline derivatives.
PA8495001A1 (en) NEW CRYSTAL FORMS OF AN ANTIBIOTIC MACROLIDO.
AR002978A1 (en) Benzamide compounds, pharmaceutical compositions containing them, methods of preparing the same and the use thereof.
MX9303574A (en) HETERO-CYCLE COMPOUNDS THAT ARE INHIBITORS OF THE AROMATASE ENZYME, PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.